New Antibody Medication Targets Alzheimer's Cause

The new medication Donane MAP binds to protein plaques in the brain typical of Alzheimer's. In clinical studies, the therapy slowed disease progression by approximately 30 percent over an 18-month period. Professor Agnes Flöhl of the neurological clinic at Greifswald University Medicine noted the effect is measurable but often barely noticeable to patients. The medication is administered via infusion every four weeks. Previous substances only stabilized patient conditions by altering brain metabolites without addressing the underlying cause. These new antibodies target the amyloid beta protein responsible for the disease.